You are here

Effect of Protein on 5-Fluorouracil and Cyclophosphamide

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 21974
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1993
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2257 South 1100 East
Salt Lake City, UT 84106
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Nathalie Chevreau
 (801) 485-4991
Business Contact
Phone: () -
Research Institution
N/A
Abstract

Feeding rats a semipurified diet containing casein as a protein source results in severe gastrointestinal (GI) toxicity when the chemotherapeutic drug methotrexate (MTX) is given. However, when soy concentrate protein is used in place of casein, rats are completely protected from toxicity. The purpose is to determine if soy concentrate protein is protective against cyclophosphamide (CY) and 5-fluorouracil (5-FU) toxicity in rats. 5-fluorouracil is a chemotherapeutic drug that causes severe side effects to the GI tract because of its effect on cell division. If soy concentrate proves to be protective in toxicity associated with chemotherapy, it could easily be incorporated into an enteral product and be tested in cancer patients to boost their nutrient intake. This soy product would help to maintain patients' adequate nutrition and, therefore, their nutritional status which has been shown to increase tolerance to chemotherapy. Further, if toxic side effects were minimized, it may be possible to increase doses of drugs and more effectively kill tumor cells.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government